Biosceptre
- Company typePrivate
- Founded2014
- HeadquartersBabraham, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Biosceptre firmographics
Firmographics- Name
- Biosceptre
- Legal name
- Biosceptre International Limited
- Website
- https://biosceptre.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Biosceptre industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)
- akta.pro secondary industries
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where Biosceptre is headquartered
LocationHeadquarters
- HQ city
- Babraham
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Biosceptre business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Therapeutic Development & Licensing: As a clinical-stage biotech, Biosceptre is pre-revenue. The company develops novel cancer therapeutics targeting nfP2X7 across multiple modalities (antibodies, vaccines, CAR-T). Future revenue would likely come from licensing agreements with pharmaceutical partners, co-development deals, and eventual product commercialization.
- Research Grants & Government Funding: Biosceptre has received multiple government-backed grants including UK Innovate UK SMART Award (£100,000), Technology Strategy Board Award (£150,000), and NHMRC Development Grant support. These non-dilutive funding sources support preclinical and clinical development programs.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Biosceptre product offering
Product offeringCore offering
Biosceptre is a clinical-stage biotechnology company developing novel cancer therapeutics that target the non-functional P2X7 (nfP2X7) receptor, a cancer-specific antigen expressed across many cancer types but absent from healthy tissue. Its pipeline spans multiple modalities, including systemic monoclonal antibodies (BIL-03s), peptide vaccines (BIL06v), topical antibody therapy (BIL010t) for basal cell carcinoma, and the BRiDGECAR™ modular CAR-T platform.
Product overview
Biosceptre is a biotechnology company developing a platform of cancer therapeutics targeting nfP2X7 (non-functional P2X7). The core technology centers on the BRiDGECAR™ System, a multiple-targeted universal CAR T platform that combines nfP2X7-targeted universal CAR T with multiple targeted antibodies. The product portfolio includes three clinical-stage candidates: BIL-03s (systemic human domain antibody for solid tumors), BIL06v (therapeutic peptide vaccine for solid tumors), and BIL010t (topical antibody treatment for Basal Cell Carcinoma). The company also offers the BridgeCAR™ Platform as an Adaptor CAR-T platform with a CD33-targeted AML module positioned for first-in-human evaluation. All products in the pipeline target the proprietary nfP2X7 receptor, a tumor-specific target absent from healthy tissue.
Differentiator
Problem solved
Functional benefit
Brands
- BRiDGECAR™: A universal CAR T system combining nfP2X7-targeted universal CAR T with multiple targeted antibodies for potential treatment of most forms of cancer.
- BridgeCAR™
Products and services
- BRiDGECAR™ System
Quantifiable outcome
- 65% of BCC patients showed reduction in lesion area with BIL010t topical treatment
- +3 more outcomes
Companies that use Biosceptre
Customer profileSegments3 records
Ideal customer profiles3 records
Biosceptre technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Biosceptre partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered major, core and minor.
- Garvan Institute of Medical ResearchmajorBiosceptre's ongoing collaboration with Garvan on antibody development and optimisation has yielded promising monoclonal antibodies. Garvan's innovative protein design work uses x-ray crystallography, phage display and mutagenesis to humanize anti-peptide antibodies and modulate affinity. The work is supported by an NHMRC Development Grant.
- University of Technology Sydney (UTS)majorBiosceptre partnered with UTS to establish a new analytical laboratory within the university's Biologics Innovation Facility (BIF). BIF is the only facility of its kind in an Australian University and the NSW node of the National Biologics Facility. The partnership provides translational support in antibody characterisation and development for Biosceptre's therapeutic programs.
- Carina BiotechcoreBiosceptre acquired exclusive rights to Carina Biotech's nfP2X7-targeted CAR-T cells and associated intellectual property. Carina received upfront cash payment and equity in Biosceptre. The companies collaborate to further develop the nfP2X7 CAR-T program towards clinical trials. This represents Carina's first commercial agreement involving their proprietary CAR-T technology.
- COST Group BMBS 1406minorBiosceptre joined the COST Group (European Cooperation in Science & Technology) project COST BMBS 1406, which created the Ion chan-Immune response network bringing together scientists and companies across 15 European countries to understand the function of ion channels in immune cells. P2X7 is central to the group's interest.
Scale indicators8 records
Recent moves7 records
Expansion highlights5 records
Biosceptre competitors and assessment
Company assessmentDirect peers
- Adaptimmune: Clinical-stage cell therapy company developing SPEAR T-cell receptor therapies for solid tumors. Comparable to Biosceptre in modality (engineered T-cell therapy), stage (Phase I/II clinical), and target market (hard-to-treat solid tumors), with a similarly focused pipeline addressing limitations of conventional CAR-T.
- Fate Therapeutics: Clinical-stage cell therapy company developing iPSC-derived NK and T-cell therapies for cancer. Comparable in modality (engineered cell therapy), stage (clinical), and oncology focus, with a platform approach to off-the-shelf cell-based cancer treatments.
- Marker Therapeutics: Clinical-stage immuno-oncology company developing multi-tumor-associated antigen-specific T-cell therapies. Comparable in modality (T-cell therapy), stage (clinical), and focus on addressing solid tumors and hematologic malignancies with novel cell therapy approaches.
- Carina Biotech: Australian clinical-stage biotech developing nfP2X7-targeted CAR-T cells and related oncology cell therapies. Biosceptre acquired exclusive rights to Carina's CAR-T technology in 2020, making them a direct technology peer and former collaborator working on the same target.
- Cellectis: Clinical-stage gene editing company developing allogeneic CAR-T cell therapies (UCART). Direct peer in CAR-T modality, gene-edited cell therapy technology, and clinical-stage oncology focus, with comparable pipeline scope and platform approach.
- Allogene Therapeutics: Clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for cancer. Directly comparable in CAR-T modality and oncology focus, with a pipeline targeting hematologic malignancies and solid tumors using off-the-shelf cell therapy approaches.
- Crispr Therapeutics: Clinical-stage gene editing company developing CRISPR/Cas9-based gene-edited cell therapies (CASGEVY) for oncology and other indications. Comparable in gene-modified cell therapy modality, clinical-stage pipeline, and oncology focus with off-the-shelf CAR-T programs.
- Precision Biosciences: Clinical-stage gene editing company developing allogeneic CAR-T cell therapies using its ARCUS genome editing platform. Comparable in modality (CAR-T cell therapy), stage (clinical), and oncology focus with both hematologic and solid tumor programs.
Broad incumbents
- Gilead Sciences (Kite Pharma): Large biopharmaceutical company with Kite Pharma division developing and commercializing approved CAR-T therapies (Yescarta, Tecartus). Overlaps with Biosceptre in CAR-T modality and oncology focus, but operates at massive scale with multiple approved products and global commercial infrastructure.
Regional players
- Imugene: Australian clinical-stage immuno-oncology company developing cancer vaccines and B-cell immunotherapies (similar size, Australian operations, comparable development stage). Shares Biosceptre's Australian clinical trial site footprint and oncology vaccine modality overlap with the BIL06v peptide vaccine program.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Biosceptre social profiles
Digital presenceBiosceptre financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biosceptre leadership team
Management profileNumber of profiles
Profiles11 records
Biosceptre subsidiaries and ownership
Company hierarchySubsidiaries2 records
Biosceptre funding detail
Funding detailFunding overview
Funding rounds8 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biosceptre M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biosceptre
What does Biosceptre do?
Biosceptre is a clinical-stage biotechnology company developing novel cancer therapeutics that target the non-functional P2X7 (nfP2X7) receptor, a cancer-specific antigen expressed across many cancer types but absent from healthy tissue. Its pipeline spans multiple modalities, including systemic monoclonal antibodies (BIL-03s), peptide vaccines (BIL06v), topical antibody therapy (BIL010t) for basal cell carcinoma, and the BRiDGECAR™ modular CAR-T platform.
Is Biosceptre a public or private company?
Biosceptre is a private company. It is classified as venture growth investor backed and is currently operating.
When was Biosceptre founded?
Biosceptre was founded in 2014. It employs 11 to 50 people.
Where is Biosceptre based?
Biosceptre is headquartered in Babraham, United Kingdom, in the Europe region.
How does Biosceptre make money?
Two revenue lines are on record. Therapeutic Development & Licensing is the primary driver. The others are research Grants & Government Funding.
Who are Biosceptre's main competitors?
Direct peers on record are Adaptimmune, Fate Therapeutics, Marker Therapeutics, Carina Biotech, Cellectis, Allogene Therapeutics, Crispr Therapeutics and Precision Biosciences. Gilead Sciences (Kite Pharma) is listed as a broad incumbent. Imugene is listed as a regional player.
Does Biosceptre have an API?
No public API is recorded for Biosceptre.
What industry is Biosceptre in?
Biosceptre's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 541714 and its SIC code is 2836.